Interfering with the glomerular hemodynamics by the means of ACE-inhibitors/sartans or SGLT2 inhibitors attenuates the hyperfiltration and reduces proteinuria, thereby slowing down the progression of DKD [51]. Here, SLC5A2 is linked to diabetic kidney disease.